Dynavax and U.S. Department of Defense Announce Collaboration to Develop an Adjuvanted Plague Vaccine Using Dynavax’s CpG 1018 Adjuvant

EMERYVILLE, Calif.: EMERYVILLE, Calif., Oct. 4, 2021 /PRNewswire/ -- Dynavax Technologies Corporation (Nasdaq: DVAX), a biopharmaceutical company focused on developing and commercializing vaccines, and the U.S. Department of Defense (DOD) today announced Dynavax has executed an agreement for approximately $22 million over two and a half years to develop a...

Click to view original post